Two medtech companies are partnering to bring software which supports people living with multiple sclerosis (MS) into new markets.
Brainomix has partnered with Pixyl to distribute the Pixyl.Neuro.MS Software as a Service (SaaS) solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe.
The software, developed by medical neurology imaging specialist Pixyl, is used in the diagnosis and treatment of patients with MS.
The revolutionary deep-learning technology allows radiologists and clinicians to quickly access clinically relevant information for neurological disorders.
The CE-marked class IIa product Neuro.MS automatically analyzes brain MRI images to identify, quantify and track abnormalities in under five minutes. This provides access to quantified measures of lesion volume and brain atrophy, as well as white matter hyperintensities, which are quantified and classified.
Brainomix, an AI-powered medtech solutions company, is now supporting the expansion of its adoption through the new partnership agreement.
Pixyl’s Neuro.MS solution will be offered to Brainomix’s existing customer base alongside Brainomix’s e-Stroke platform, the world’s most comprehensive stroke imaging solution, which is widely adopted in multiple healthcare systems worldwide, supporting physicians to allow more patients to be treated in the right place, at the right time.
“We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions,” said Dr Michalis Papadakis, co-founder and CEO of Brainomix.
“We recognised that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions.
“We have achieved great success with our e-Stroke platform, and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”
“Leveraging Brainomix’s large installed base and dedicated sales force in some of Europe’s leading markets represents a strategic step in our vision to broaden the adoption of AI-powered, clinically relevant solutions to drive better patient outcomes in the neurology imaging space,” said Dr Senan Doyle, co-founder and CEO of Pixyl.
The emergence of disease-modifying drugs now offers more personalised treatment of MS, a neurological disorder that affects more than 2.3 million people worldwide.
This has elevated the role of MRI in supporting both the diagnosis and ongoing disease monitoring and treatment response, opening the door for AI-powered solutions such as Pixyl’s Neuro.MS software to improve diagnosis and speed up treatment.
